Champions Oncology Inc (CSBR) Expected to Announce Quarterly Sales of $6.38 Million

Wall Street analysts expect Champions Oncology Inc (NASDAQ:CSBR) to announce $6.38 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Champions Oncology’s earnings, with the highest sales estimate coming in at $6.60 million and the lowest estimate coming in at $6.15 million. Champions Oncology posted sales of $4.92 million during the same quarter last year, which suggests a positive year-over-year growth rate of 29.7%. The company is scheduled to report its next earnings results on Thursday, July 25th.

According to Zacks, analysts expect that Champions Oncology will report full-year sales of $26.00 million for the current financial year. For the next fiscal year, analysts forecast that the business will report sales of $31.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Champions Oncology.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Champions Oncology from a “strong sell” rating to a “hold” rating in a research note on Monday, March 18th. National Securities assumed coverage on shares of Champions Oncology in a research report on Wednesday, February 27th. They issued a “buy” rating and a $17.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Champions Oncology has an average rating of “Buy” and an average target price of $12.75.



A number of institutional investors have recently made changes to their positions in the business. Battery Partners IX LLC lifted its position in Champions Oncology by 3.0% during the first quarter. Battery Partners IX LLC now owns 2,011,882 shares of the biotechnology company’s stock valued at $19,696,000 after purchasing an additional 58,333 shares during the last quarter. Cadence Capital Management LLC lifted its position in Champions Oncology by 122.2% during the first quarter. Cadence Capital Management LLC now owns 273,335 shares of the biotechnology company’s stock valued at $2,676,000 after purchasing an additional 150,325 shares during the last quarter. Renaissance Technologies LLC lifted its position in Champions Oncology by 164.3% during the third quarter. Renaissance Technologies LLC now owns 265,846 shares of the biotechnology company’s stock valued at $4,644,000 after purchasing an additional 165,246 shares during the last quarter. Vanguard Group Inc lifted its position in Champions Oncology by 51.4% during the third quarter. Vanguard Group Inc now owns 231,150 shares of the biotechnology company’s stock valued at $4,038,000 after purchasing an additional 78,428 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Champions Oncology by 51.4% during the third quarter. Vanguard Group Inc. now owns 231,150 shares of the biotechnology company’s stock valued at $4,038,000 after purchasing an additional 78,428 shares during the last quarter. Institutional investors and hedge funds own 53.25% of the company’s stock.

Shares of CSBR traded down $0.08 during trading hours on Wednesday, hitting $8.50. The company’s stock had a trading volume of 22,900 shares, compared to its average volume of 56,897. The company has a market capitalization of $97.06 million, a price-to-earnings ratio of -60.71 and a beta of 1.42. Champions Oncology has a 52-week low of $3.92 and a 52-week high of $17.90.

About Champions Oncology

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Read More: What is the Producer Price Index (PPI)?

Get a free copy of the Zacks research report on Champions Oncology (CSBR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.